Skip to main content
Wiley - PMC COVID-19 Collection logoLink to Wiley - PMC COVID-19 Collection
. 2021 Feb 8;97(4):377–378. doi: 10.1111/tan.14199

A novel allele, HLA‐C*15:227, identified when typing COVID‐19 patients

Valery Cheranev 1,, Maria Loginova 2, Tatjana Jankevic 1, Svetlana Kutyavina 2, Denis Rebrikov 1
PMCID: PMC8013338  PMID: 33539638

Abstract

HLA‐C*15:227 differs from HLA‐C*15:02:01:01 by a single nonsynonymous change (368A → G Tyrosine 99 to Cysteine).

Keywords: HLA‐C*15:227, NGS HLA typing, novel HLA allele


The IPD‐IMGT/HLA Database currently has information on more than 20,000 human leukocyte antigen (HLA) class I alleles and more than 6200 of these are alleles of HLA‐C gene. 1 In this report, we describe the sequence of a novel HLA‐C allele. It was identified in a COVID‐19 patient, using a next‐generation sequencing (NGS) method for HLA typing.

The genomic DNA was extracted from peripheral blood cells using a commercial kit “Proba MCh‐Max,” according to the manufacturer's instructions (DNA‐technology, Moscow, Russia) on automatic DNA extraction station “DT‐stream” (DNA‐technology, Moscow, Russia). It was typed for HLA‐alleles at the A, B, C, DRB1, and DQB1 loci using reagents “HLA‐expert” (DNA‐technology, Moscow, Russia), sequenced on MiSeq (Illumina, The United States), and analyzed with “HLA‐expert” software (DNA‐technology, Moscow, Russia).

The sequence of HLA‐C*15:227 differs from HLA‐C*15:02:01:01 by nonsynonymous mutation (A → G) at position 368, resulting in change from TAT (Tyrosine) to TGT (Cysteine) at codon 99 in exon 3. The complete HLA typing of patient with the novel HLA‐C*15:227 allele was: HLA‐A*29:02:01G, 32:01:01G; HLA‐C*06:02:01G, 15:227; HLA‐B*50:01:01G, 51:01:01G; HLA‐DRB1*04:04:01G, 07:01:01G; HLA‐DQB1*02:01:01G, 03:02:01G.

The novel allele was submitted to GenBank (accession number MT896389) and the IPD‐IMGT/HLA Database 1 and was officially assigned by the World Health Organization (WHO) Nomenclature Committee for Factors of the HLA System in September 2020. List of such new names were published in the following WHO Nomenclature Report. 2

The HLA‐C*15:227 allele was confirmed in the Research Laboratory of Applied Immunogenetics by NGS typing with the VariFind HLA solution IL kit (Parseq Lab Co, Saint Petersburg, Russia), the whole HLA‐C (except the 3′‐UTR region) gene was amplified by long PCR at 1st step. Once the library for NGS was obtained, it was then sequenced using a MiSeq (Illumina, The United States) and analyzed by VariFind HLA Software v2.2 (Parseq Lab Co, Saint Petersburg, Russia).

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

AUTHOR CONTRIBUTIONS

Valery Cheranev: Registering novel allele. Maria Loginova: Confirmatory HLA‐typing, writing a manuscript. Tatjana Jankevic: Primary HLA‐typing. Svetlana Kutyavina: Confirmatory HLA‐typing. Denis Rebrikov: Recruiting bone marrow donors, collection blood samples.

ACKNOWLEDGMENT

This research was funded by grant number 075‐15‐2019‐1789 from the Ministry of Science and Higher Education of the Russian Federation allocated to the Center for Precision Genome Editing and Genetic Technologies for Biomedicine.

Cheranev V, Loginova M, Jankevic T, Kutyavina S, Rebrikov D. A novel allele, HLA‐C*15:227, identified when typing COVID‐19 patients. HLA. 2021;97:377–378. 10.1111/tan.14199

Funding information Ministry of Science and Higher Education of the Russian Federation, Grant/Award Number: 075‐15‐2019‐1789

DATA AVAILABILITY STATEMENT

Data is available from the IPD‐IMGT/HLA Database. GenBank accession number‐MT896389.

REFERENCES

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Data is available from the IPD‐IMGT/HLA Database. GenBank accession number‐MT896389.


Articles from Hla are provided here courtesy of Wiley

RESOURCES